Holen Sie sich die Stockscreener-App
42.49
0.29%
0.1121
Qiagen Nv Aktie (QGEN) Neueste Nachrichten
Qiagen (NYSE:QGEN): Can Its New Launch Unlock Value? - Kalkine Media
UBS Adjusts Price Target on QIAGEN to $47 From $52, Keeps Neutral Rating - marketscreener.com
Qiagen stock holds steady as analysts see limited upside - AD HOC NEWS
Qiagen N.V. $QGEN Stake Reduced by Allianz Asset Management GmbH - MarketBeat
Qiagen stock heads into the open after a 0.25 percent dip - AD HOC NEWS
PTA-DD: QIAGEN N.V.: Managers' transactions announcement according to article 19 MAR - TradingView
Managers' transactions announcement according to article 19 MAR - TradingView
Groupe la Francaise Has $3.25 Million Stake in Qiagen N.V. $QGEN - MarketBeat
Qiagen stock heads into the open after a 2.0 percent drop - AD HOC NEWS
Qiagen stock edges lower as investors look beyond recent earnings - AD HOC NEWS
Qiagen N.V. (QGEN) Stock Analysis: Exploring The 5.98% Potential Upside For Investors - DirectorsTalk Interviews
New CEO took over the reins - European Biotechnology Magazine
Qiagen stock heads into the open after a muted move on Xetra - AD HOC NEWS
Public Employees Retirement System of Ohio Purchases New Shares in Qiagen N.V. $QGEN - MarketBeat
Qiagen (QGEN) Beat Q2 Estimates And Reaffirmed Outlook, Is It Still Below Fair Value? - Yahoo Finance
Qiagen N.V.ADR Key Financial Ratios – Valuation, Profitability & More - Value Research
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Qiagen stock trades around 43 dollars as investors watch margins and diagnostics demand - AD HOC NEWS
Qiagen (QGEN) Up 5.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Global Multiplex Assays Market 2026 Edition - GlobeNewswire Inc.
Qiagen stock holds steady as margins and stake disclosure support valuation - AD HOC NEWS
BlackRock Discloses Significant Stake in Qiagen Under AFM Rules - The Globe and Mail
Qiagen stock holds near 43 dollars as stake disclosure and margins support valuation - AD HOC NEWS
Qiagen stock holds near 43 dollars after steady analyst view - AD HOC NEWS
Release according to Article 40, Section 1 of the WpHG - TradingView
Qiagen NV at Citi Global Healthcare Conference Transcript - GuruFocus
Qiagen stock steadies near 43 dollars as latest quarter shows modest growth - AD HOC NEWS
Q3 2025 Qiagen NV Earnings Call Transcript - GuruFocus
Qiagen stock holds mid-40 dollar level as analysts stick to hold ratings - AD HOC NEWS
Plant Virome Diagnostics Outlook 2026-2030 Featuring Profiles of Illumina, Thermo Fisher Scientific and Qiagen - Yahoo Finance
Qiagen N.V. (NYSE:QGEN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
List of 26 Acquisitions by Qiagen (Sep 2026) - Tracxn
Qiagen stock steadies around $43 as investors digest legal and ownership signals - AD HOC NEWS
Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit - Benzinga
Qiagen N.V. (QGEN) Stock Analysis: Navigating Potential Upside In Healthcare Diagnostics - DirectorsTalk Interviews
Delaware jury finds Parse infringed three genetic-sequencing patents - Reuters
Wellington Management Group LLP Trims Stock Position in Qiagen N.V. $QGEN - MarketBeat
Goldman Sachs Revealed as 2.97% Shareholder in Qiagen via AFM Filing - The Globe and Mail
Bank of America Reports 4.69% Stake in Qiagen - The Globe and Mail
Could Qiagen (QGEN) Stock Win as Its FDA Clearance Opens a New Diagnostics Market? - Yahoo Finance
10x Genomics wins jury award in Qiagen patent row (TXG:NASDAQ) - Seeking Alpha
10x Genomics Announces $4.8 Million Award in Patent Case Against Qiagen Unit - marketscreener.com
QIAGEN Launches QIAsymphony Connect for Automated Nucleic Acid Extraction - Clinical Lab Products
Qiagen launches automated nucleic acid extraction platform - Investing.com
Zacks Research Has Pessimistic Outlook of Qiagen Q3 Earnings - MarketBeat
QIAGEN Names Former Beckman Coulter President as CEO - Medical Product Outsourcing
Two potential buyers begin formal due diligence in Qiagen sales processreport (QGEN:NYSE) - Seeking Alpha
Qiagen N.V. Appoints Jonathan M. Pratt as Chief Executive Officer, Effective September 1, 2026 - marketscreener.com
QIAGEN N.V.: QIAGEN appoints Jonathan M. Pratt as Chief Executive Officer - marketscreener.com
Qiagen names Jonathan Pratt as CEO amid takeover talks - Investing.com
Wellington Discloses 5.1% Voting Stake in Qiagen via AFM Filing - The Globe and Mail
Qiagen stock trades just below analyst target as latest earnings underpin valuation - Ad-hoc-news.de
Qiagen stock slips despite Q2 earnings beat and stable guidance - Ad-hoc-news.de
Qiagen stock holds steady as recent earnings support valuation - Ad-hoc-news.de
PTA-AFR: QIAGEN N.V.: Pre-announcement of a financial report according to articles 114117 WpHG - TradingView
Qiagen stock advances after topping DAX winners with fresh gain - Ad-hoc-news.de
Qiagen stock holds steady as merger terms clarify for investors - Ad-hoc-news.de
Qiagen NV (QGEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Qiagen NV at Leerink Global Healthcare Conference Transcript - GuruFocus
Qiagen NV Annual Shareholders Meeting Transcript - GuruFocus
Qiagen (QGEN) Price Action: Loses 0.66% to Close at $42.32 on the Day; Trading Range: the Price Remains Bounded by the Supplied Support and Resistance in the Latest SessionQuote Data - vinanet.vn
Qiagen stock steady after Q2 2026 earnings beat and guidance reaffirmation - Ad-hoc-news.de
One Fin Capital Management LP's Qiagen NV(QGEN) Holding History - GuruFocus
A Quick Look at Today's Ratings for Qiagen NV(QGEN.US), With a Forecast Between $45.5 to $46.09 - Moomoo
Qiagen stock trades just under analyst targets as Q2 2026 beat supports steady outlook - ad-hoc-news.de
Qiagen stock holds steady after Q2 2026 beat and guidance reaffirmation - ad-hoc-news.de
Qiagen N.V. (QGEN) Stock Analysis: Exploring Its Growth Potential and Strategic Position in Diagnostics - DirectorsTalk Interviews
Handelsbanken Fonder AB Takes $2.91 Million Position in Qiagen N.V. $QGEN - MarketBeat
2.30%
0.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):